HEALTH
- Share via
Sues Over Rival Drug: The company alleges in a lawsuit filed in federal court in Delaware that an Ortho Pharmaceutical Corp. drug that stimulates production of red blood cells infringes a Genetics patent. In dispute is homogenous erythropoietin, known as EPO, which Genetics said has annual worldwide sales of $1 billion. Ortho, a unit of New Brunswick, N.J.-based Johnson & Johnson, sells an EPO drug called Procrit. Genetics said the patent in question was issued to the company Monday. Genetics is majority-owned by American Home Products Corp., based in Madison, N.J. Genetics, which said it discovered how to refine and purify EPO produced in animal cells, earns $20 million a year in royalties on EPO products made and sold in Europe and Japan. Procrit is made by Amgen Inc. and is sold by Ortho in the United States
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.